Norquist et al. [17] observed that 6.8% of the ovarian cancer patients included in the GOG 218 trial harbored a non-BRCA somatic HR gene mutation, and the most frequently observed alteration was in ATM. This evidence concerns the gene ATM and ovarian carcinoma.